+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

NEWGAM - Emerging Insight and Market Forecast - 2030

  • PDF Icon

    Report

  • 30 Pages
  • February 2021
  • Region: Global
  • DelveInsight
  • ID: 5304316
UP TO OFF until Dec 31st 2022
“NEWGAM - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic inflammatory demyelinating Syndromein 7 Major Markets. A detailed picture of the NEWGAM in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview


Panzyga® (NEWGAM) is a 10% human normal immunoglobulin solution ready for intravenous administration. The manufacturing process achieves a significant viral reduction through a combination of three dedicated manufacturing process steps: solvent/detergent treatment, ion-exchange chromatography and nanofiltration (20 nm) and thus complies with the latest international consensus on best practices for viral safety. Panzyga® is approved for use in treatment of primary immunodeficiency and idiopathic thrombocytopenic purpura in several countries.

Scope of the Report


The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around NEWGAM.
  • The report contains forecasted sales for NEWGAM till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Chronic inflammatory demyelinating Syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of NEWGAM.

Methodology


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NEWGAM Analytical Perspective


In-depth NEWGAM Market Assessment


This report provides a detailed market assessment of NEWGAM in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

NEWGAM Clinical Assessment


The report provides the clinical trials information of NEWGAM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Chronic inflammatory demyelinating Syndromeis set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence NEWGAM dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic inflammatory demyelinating Syndromeare giving market competition to NEWGAM and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of NEWGAM.
  • This in-depth analysis of the forecasted sales data of NEWGAM from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NEWGAM.

Key Questions Answered

  • Which company is developing NEWGAM along with the phase of the clinical study?
  • What is the technology utilized in the development of NEWGAM?
  • What is the product type, route of administration and mechanism of action of NEWGAM?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NEWGAM development?
  • What are the key designations that have been granted to NEWGAM?
  • What is the forecasted market scenario of NEWGAM?
  • What is the history of NEWGAM and what is its future?
  • What is the forecasted sales of NEWGAM in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to NEWGAM?
  • Which are the late-stage emerging therapies under development for the treatment of the Chronic inflammatory demyelinating Syndrome?

Table of Contents

1. Drug Overview
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. Market Assessment
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT Analysis4. Analyst Views5. Market Competitors6. Other Emerging Therapies7. Appendix8. Report Purchase Options
List of Tables
Table 1 NEWGAM, Description
Table 2 NEWGAM, Clinical Trial Description
Table 3 NEWGAM, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
List of Figures
Figure 1 The Development Timeline of NEWGAM
Figure 2 Patent Details, NEWGAM
Figure 3 NEWGAM, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 NEWGAM, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 NEWGAM, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 NEWGAM, Japan Market Size from 2020 to 2030 (in Millions USD)